News

September 22, 2015 3:45 pm
Takeda Pharmaceutical Company Limited on September 22, 2015 announced that it will highlight the ixazomib clinical development program during multiple poster sessions at the upcoming 15th International Myeloma Workshop (IMW 2015) to be held in Rome...
September 22, 2015 3:45 pm
  The US Food and Drug Administration (FDA) has agreed for priority review of Amgen’s supplemental new drug application (sNDA) for expanded labeling of Kyprolis (carfilzomib) in relapsed multiple myeloma.
September 16, 2015 10:00 am
Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to the New Drug Application (NDA) for ixazomib, the first investigational oral proteasome inhibitor for the...
September 16, 2015 9:45 am
Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for daratumumab as a treatment for patients with multiple myeloma...

Pages